# Tolerability of MDMA in Schizophrenia

> **NCT05770375** · PHASE1,PHASE2 · RECRUITING · sponsor: **Anya Bershad, MD, PhD** · enrollment: 20 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** MDMA 40mg
- **DRUG:** MDMA 80mg
- **DRUG:** MDMA 120mg

## Key facts

- **NCT ID:** NCT05770375
- **Lead sponsor:** Anya Bershad, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-01
- **Primary completion:** 2027-03
- **Final completion:** 2028-03
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-03-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05770375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05770375, "Tolerability of MDMA in Schizophrenia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05770375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*